Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Dr Ip on the Implications of NGS Plus Machine Learning for Diagnosing Hematologic Malignancies

April 4th 2024

Andrew Ip, MD, discusses the implications of using next-generation sequencing alongside machine learning in the diagnosis of hematologic malignancies.

Revumenib Demonstrates Activity in Pediatric Patients With KMT2A+ Acute Leukemia

April 4th 2024

Phase 2 data from the AUGMENT-101 study show that revumenib elicits responses with acceptable safety in pediatric patients with KMT2A+ acute leukemia.

Patient Insurance Status and Out-of-Pocket Costs Affect Genomic Testing Frequency

April 2nd 2024

As genomic testing becomes ubiquitous in cancer care, some patients experience out-of-pocket costs that may affect oncologists’ genetic testing decisions.

Clinicians Express Reservations Around Ethical Issues of AI in Cancer Care

April 1st 2024

A survey of practicing oncologists in the United States revealed that clinicians have ethical concerns surrounding the use of AI in cancer care.

Establishing Biomarkers Is Key to Driving Personalized Systemic Treatment Choices in Advanced RCC

March 30th 2024

Wenxin (Vincent) Xu, MD, discusses the evolving landscape of systemic therapy in RCC, sharing how he makes treatment decisions amid the changing treatment space.

All Eyes Are on IL-15 in Early Phase Studies

March 29th 2024

A deep dive into IL-15 targeted agents including N-803, those in the pipeline, and the fusion protein SAR445877 which Martin E. Gutierrez, MD, sheds light on.

Adagrasib Improves PFS, ORR in Previously Treated KRAS G12C–Mutant NSCLC

March 28th 2024

Adagrasib improved progression-free survival and objective response rates vs docetaxel in pretreated KRAS G12C–mutant non–small cell lung cancer.

MK-1084 Alone and Plus Pembrolizumab Shows Early Safety, Activity in KRAS G12C+ Solid Tumors

March 27th 2024

MK-1084 had an acceptable toxicity profile when administered as a monotherapy in patients with KRAS G12C–mutated previously treated solid malignancies.

Capivasertib/Fulvestrant Wins Approval in Japan for Advanced HR+/HER2– Breast Cancer With PIK3CA, AKT1, or PTEN Alterations

March 27th 2024

Capivasertib plus fulvestrant has been approved in Japan for pretreated, PIK3CA-, AKT1-, or PTEN-altered, HR-positive, HER2-negative breast cancer.

Dr Amini on High-Risk Factors Associated With Cardiac Toxicities in Lung Cancer

March 22nd 2024

Arya Amini, MD, discusses cardiac toxicities associated with lung cancer.

Dr Masters on the 2024 ACRO Summit

March 21st 2024

Adrianna Masters, MD, PhD, discusses pivotal events from the 2024 ACRO Summit, emphasizing the importance of mentorship in radiation oncology.

FDA Accepts NDA for Ensartinib in Metastatic ALK+ NSCLC

March 13th 2024

The FDA has accepted a new drug application for ensartinib in metastatic ALK-positive non–small cell lung cancer.

TERN-701 Receives FDA Orphan Drug Designation in CML

March 12th 2024

TERN-701 has received orphan drug designation from the FDA for the treatment of patients with chronic myeloid leukemia.

Targeted Delivery of IL-12 Shows Preliminary Antitumor Activity in Advanced Solid Tumors

March 11th 2024

A high proportion of patients with metastatic solid tumors experienced stable disease following treatment with the immunocytokine in the DODEKA trial.

ABSK061 Demonstrates Safety, Preliminary Efficacy in FGFR2/3+ Advanced Solid Tumors

March 7th 2024

ABSK061 was well tolerated and elicited responses in patients with advanced solid tumors harboring FGFR2/3 alterations.

FDA Approval Highlights: OncLive’s February Recap

February 29th 2024

In case you missed it, below is a recap of all drugs that have been approved by the FDA in February 2024.

Revisit Every OncLive On Air Episode From January 2024

February 26th 2024

In case you missed it, read a recap of every episode of OncLive On Air recorded in January 2024.

Dr Kim on the Importance of the FDA Approval of Repotrectinib for ROS1+ NSCLC

February 23rd 2024

Chul Kim, MD, MPH, discusses the impact of optimizing rare targets in lung cancer, highlighting the FDA approval of repotrectinib in ROS1-positive disease.

Reflex Molecular Testing May Enhance Targeted Therapy Benefit in Early-Stage Lung Cancer

February 19th 2024

Jobelle Baldonado, MD, highlights the emergence of targeted therapies and the need for reflex-ordered molecular testing in early-stage lung cancer.

FDA Approves Tepotinib for Metastatic NSCLC Harboring MET Exon 14 Skipping Alterations

February 15th 2024

The FDA has granted approval to tepotinib (Tepmetko) for adult patients with metastatic non–small cell lung cancer harboring MET exon 14 skipping alterations.